

**KURZPROTOKOLL
POSITIVE**

Öffentlicher Titel	Biomarkerstudie bei Hirnmetastasen
Wissenschaftl. Titel	Prospective serial profiling of CSF in patients with brain metastases to generate predictive biomarkers
Kurztitel	POSITIVE
Studienart	multizentrisch, prospektiv, offen/unverblindet, einarmig, nicht-interventionelle Studie, Investigator Initiated Trial (IIT)
Studienphase	nicht zutreffend
Erkrankung	Nervensystem: sonstige
Einschlusskriterien	<ul style="list-style-type: none">- suspicion of brain or leptomeningeal metastases from solid tumors as assessed by cerebral imaging (MRI)- interdisciplinary recommendation for surgery/biopsy of the brain metastasis is considered- interdisciplinary recommendation for postoperative stereotactic radiosurgery (SRS) is considered- interdisciplinary recommendation for systemic therapy is considered- Karnofsky performance status ≥ 50, ECOG ≤ 2- INR $\leq 1,7$, Quick $> 50\%$, thrombocytes $> 50000/\mu\text{L}$- disorder of coagulation- treatment with anticoagulant medications- other medical conditions that might increase the risk of bleeding complications- pregnancy- dementia or other clinically relevant alterations of the mental status which could impair the ability to understand the informed consent of the study- major contraindications to MRI scanning (e.g. presence of implanted MRI-incompatible cardiac devices)- major contraindications to lumbar puncture (e.g. local inflammation, increased intracerebral pressure, cardiorespiratory disease that does not allow adequate positioning of the participant for lumbar puncture)
Ausschlusskriterien	
Alter	18 Jahre und älter
Prüfzentren	Neuroonkologie (Aktiv) Schleusenweg 2-16 60528 Frankfurt am Main Dr. med. Pia Zeiner pia.zeiner@unimedizin-ffm.de Universitätsklinikum Frankfurt (Aktiv) Dr. Senckenbergisches Institut für Neuroonkologie Theodor-Stern-Kai 7 60590 Frankfurt am Main Dr. med. Pia Zeiner pia.zeiner@unimedizin-ffm.de
Sponsor	Goethe-Universität Frankfurt
Förderer	Frankfurt Cancer Institute